Bolt Biotherapeutics, Inc.
BOLT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.00 | 0.22 | -1.29 |
| FCF Yield | -96.01% | -86.74% | -4.36% | -3.52% |
| EV / EBITDA | -2.08 | -2.89 | -27.57 | -28.06 |
| Quality | ||||
| ROIC | -13.33% | -13.48% | -16.22% | -19.66% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 34.04% |
| Cash Conversion Ratio | 1.36 | 1.12 | 1.21 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | -10.30% | -14.99% | -18.59% | 10.31% |
| Free Cash Flow Growth | -2.16% | 28.19% | 7.38% | -3.02% |
| Safety | ||||
| Net Debt / EBITDA | -0.76 | -1.65 | -1.39 | -1.18 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 34.92 | 52.29 | -4.18 |